26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Fatal diffuse alveolar haemorrhage mimicking acute exacerbation in idiopathic pulmonary fibrosis treated with nintedanib

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A 75‐year‐old man was referred to our hospital with a 1‐year history of persistent dry cough and progressive dyspnoea on exertion. He was treated with aspirin due to thrombosis of internal carotid artery. He was diagnosed with idiopathic pulmonary fibrosis ( IPF)/usual interstitial pneumonia ( UIP), and started on inhaled N‐acetylcysteine therapy and pirfenidone. Since his clinical condition progressively deteriorated after 6 months, he was switched from pirfenidone to nintedanib. As a result, his general condition worsened rapidly. He was diagnosed with acute exacerbation ( AE) of IPF, and was treated with methylprednisolone pulse and recombinant human soluble thrombomodulin. Despite the administration of these treatments, he died of severe haemoptysis four days after the onset of AE. Autopsied lungs revealed significantly dark red‐brown appearance corresponding to diffuse alveolar haemorrhage ( DAH) histopathogically with a background pattern of UIP with fibrotic change. Notably, there was no evidence of diffuse alveolar damage suggesting IPF‐AE.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: not found

          The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism.

          Thrombomodulin (TM) is an endothelial anticoagulant cofactor that promotes thrombin-mediated formation of activated protein C (APC). We have found that the N-terminal lectin-like domain (D1) of TM has unique antiinflammatory properties. TM, via D1, binds high-mobility group-B1 DNA-binding protein (HMGB1), a factor closely associated with necrotic cell damage following its release from the nucleus, thereby preventing in vitro leukocyte activation, in vivo UV irradiation-induced cutaneous inflammation, and in vivo lipopolysaccharide-induced lethality. Our data also demonstrate antiinflammatory properties of a peptide spanning D1 of TM and suggest its therapeutic potential. These findings highlight a novel mechanism, i.e., sequestration of mediators, through which an endothelial cofactor, TM, suppresses inflammation quite distinctly from its anticoagulant cofactor activity, thereby preventing the interaction of these mediators with cell surface receptors on effector cells in the vasculature.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.

            Little is known about the pathobiology of acute exacerbation of idiopathic pulmonary fibrosis (IPF), a condition that shares clinical and histopathological features with acute lung injury. Plasma biomarkers have been well studied in acute lung injury and have provided insight into the underlying disease mechanism. The objective of this study was to determine the plasma biomarker profile of acute exacerbation of IPF and compare this profile with that of stable IPF and acute lung injury. Plasma was collected from patients with stable IPF, acute exacerbation of IPF, and acute lung injury for measurement of biomarkers of cellular activity/injury (receptor for advanced glycation endproducts, surfactant protein D, KL-6, von Willebrand factor), systemic inflammation (IL-6), and coagulation/fibrinolysis (protein C, thrombomodulin, plasminogen activator inhibitor-1). Plasma from patients with acute exacerbation of IPF showed significant elevations in markers of type II alveolar epithelial cell injury and/or proliferation, endothelial cell injury, and coagulation. This profile differed from the biomarker profile in patients with acute lung injury. These findings support the hypothesis that type II alveolar epithelial cells are centrally involved in the pathobiology of acute exacerbation of IPF. Furthermore, they suggest that acute exacerbation of IPF has a distinct plasma biomarker profile from that of acute lung injury.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study.

              Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) can be fatal, and abnormalities in the coagulation system of patients with AE-IPF have been reported. Recombinant human soluble thrombomodulin (rhTM) forms a complex with thrombin to inactivate coagulation. It also inhibits high-mobility group box protein 1 (HMGB-1), which results in the suppression of inflammation.
                Bookmark

                Author and article information

                Contributors
                ks142129_ikusou@ybb.ne.jp
                Journal
                Respirol Case Rep
                Respirol Case Rep
                10.1002/(ISSN)2051-3380
                RCR2
                Respirology Case Reports
                John Wiley & Sons, Ltd (Chichester, UK )
                2051-3380
                27 August 2017
                November 2017
                : 5
                : 6 ( doiID: 10.1002/rcr2.v5.6 )
                : e00258
                Affiliations
                [ 1 ] Department of Respiratory Medicine Toho University Omori Medical Center Tokyo Japan
                [ 2 ] Department of Surgical Pathology Toho University Omori Medical Center Tokyo Japan
                Author notes
                [*] [* ] Correspondence

                Keishi Sugino, MD, PhD, Department of Respiratory Medicine, Toho University Omori Medical Center, 6‐11‐1, Omori‐nishi, Ota‐ku, Tokyo 143‐8541, Japan. E‐mail: ks142129_ikusou@ 123456ybb.ne.jp

                Author information
                http://orcid.org/0000-0003-3688-6782
                Article
                RCR2258
                10.1002/rcr2.258
                5572108
                69cc25fc-a56d-4b7a-8789-24f376e7ff74
                © 2017 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology

                This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 05 May 2017
                : 23 July 2017
                : 29 July 2017
                Page count
                Figures: 3, Tables: 0, Pages: 3, Words: 1647
                Funding
                Funded by: Japan Agency for Medical Research and Development
                Categories
                Case Report
                Case Reports
                Custom metadata
                2.0
                rcr2258
                rcr2258-hdr-0001
                November 2017
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.8 mode:remove_FC converted:27.08.2017

                acute exacerbation,diffuse alveolar haemorrhage,idiopathic pulmonary fibrosis,nintedanib,recombinant human soluble thrombomodulin

                Comments

                Comment on this article